140 related articles for article (PubMed ID: 26678610)
1. Transcriptional kinases: Less is more (or less).
Boyer TG
Nat Chem Biol; 2016 Jan; 12(1):4-5. PubMed ID: 26678610
[No Abstract] [Full Text] [Related]
2. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
[TBL] [Abstract][Full Text] [Related]
3. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.
Cee VJ; Chen DY; Lee MR; Nicolaou KC
Angew Chem Int Ed Engl; 2009; 48(47):8952-7. PubMed ID: 19844931
[No Abstract] [Full Text] [Related]
4. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Philip S; Kumarasiri M; Teo T; Yu M; Wang S
J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
7. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
[TBL] [Abstract][Full Text] [Related]
8. HIV Transcription Is Independent of Mediator Kinases.
Cary DC; Rheinberger M; Rojc A; Peterlin BM
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):710-717. PubMed ID: 31044597
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
10. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
[TBL] [Abstract][Full Text] [Related]
11. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
12. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
13. In Search of Novel CDK8 Inhibitors by Virtual Screening.
Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery.
Martin RD; Hébert TE; Tanny JC
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397434
[TBL] [Abstract][Full Text] [Related]
15. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib (Ibrance) for metastatic breast cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
[No Abstract] [Full Text] [Related]
17. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
[TBL] [Abstract][Full Text] [Related]
18. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
19. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
